Jyong Biotech's (MENS) Sell (E+) Rating Reiterated at Weiss Ratings

Key Points

• Weiss Ratings has reiterated a "sell (e+)" rating for Jyong Biotech (NASDAQ:MENS), indicating continued negative sentiment towards the stock.
• Despite the sell rating from Weiss Ratings, Wall Street Zen upgraded Jyong Biotech to a "hold" rating, creating a divergence in analyst opinions.
• Jyong Biotech's stock has experienced a significant decline, currently down 7.2% with a recent opening price of $51.14.

Jyong Biotech (NASDAQ:MENS - Get Free Report)'s stock had its "sell (e+)" rating reiterated by Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen upgraded Jyong Biotech to a "hold" rating in a research note on Monday, June 30th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Jyong Biotech presently has an average rating of "Sell".

Jyong Biotech Stock Down 7.2%

MENS opened at $51.14 on Wednesday. The business's 50-day moving average is $48.63. Jyong Biotech has a 52-week low of $6.01 and a 52-week high of $67.00.

About Jyong Biotech

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers' health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.